Pain Therapeutics, Inc. (PTIE) Hits All-Time Low at $2.14 on Jun, 29

June 29, 2018 - By Jeanette Garcia

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. Barchart.com announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

PTIE is touching $2.14 during the last trading session, after decreased 5.10%.Pain Therapeutics, Inc. is uptrending after having risen 133.72% since June 29, 2017. PTIE has 274,326 volume or 132.03% up from normal. PTIE outperformed by 121.15% the S&P 500.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news published briefly go to: Benzinga.com, Streetinsider.com, Seekingalpha.com, Benzinga.com or Benzinga.com. The titles are as follows: “20 Stocks Moving In Thursday’s Pre-Market Session” published on June 28, 2018, “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” on June 27, 2018, “Key events next week – healthcare” with a publish date: June 21, 2018, “42 Biggest Movers From Yesterday” and the last “The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs” with publication date: June 25, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is worth $14.76 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.